Pablo Corral on Lipid-Lowering Therapy and Cognition: Evidence vs Myth
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Lipid-Lowering Therapy and Cognition: Evidence vs Myth
1. Elevated LDL-C remains the leading modifiable risk factor for cardiovascular disease and a major contributor to global mortality.
2. Concerns about cognitive adverse effects of lipid-lowering therapies (LLTs), particularly statins, are largely driven by early case reports rather than robust clinical evidence.
3. Observational studies and randomized trials consistently show no significant association between statin use and cognitive decline, with some data suggesting potential protective effects against dementia.
4. Major randomized trials (HPS, PROSPER, HOPE-3) found no difference in cognitive outcomes between statin-treated and placebo groups.
5. PCSK9 inhibitors (evolocumab, alirocumab) demonstrate neurocognitive safety, even with very low LDL-C levels and long-term exposure.
6. Ezetimibe and bempedoic acid show neutral neurocognitive profiles, with emerging signals of possible neuroprotective effects.
Current data support a clear conclusion:
- Lowering LDL-C improves cardiovascular outcomes without meaningful cognitive harm.
- The real knowledge gap is not safety, but understanding whether lipid-lowering therapies might also confer long-term neuroprotection.
Take-home message:
Fear of cognitive decline should not justify therapeutic inertia.
The price of untreated LDL-C is cardiovascular disease—not cognitive impairment.”
Read the full article here.
Article: Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations
Authors: Raiza Rossi, Armin Nouri, Zafer Akman, Shefa Arya Nezhad, Abdulla A. Damluji, Michael G. Nanna
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026